Lake Street analyst Thomas Flaten initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $9 price target Shares have recently gained traction in the market in recognition of the upcoming Seabreeze STAT readouts and the upside they may deliver to shareholders, argues the analyst, who sees “significant headroom for shares beyond today” ahead of readouts due in the first half of 2026 and as the long-term potential of rademikibart “becomes more fully understood.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Reports Significant Loss Amid Development Efforts
- Promising Outlook for Connect Biopharma Holdings Driven by Rademikibart’s Potential and Strategic Partnerships
- Buy Rating for Connect Biopharma Holdings: Rademikibart’s Market Differentiation and Safety Advantages
- Connect Biopharma reports Q3 EPS (31c), consensus (24c)
- Promising Outlook for Connect Biopharma Holdings: Rademikibart’s Potential in Asthma and COPD